ArticleThe Lancet regional health. Southeast Asia2025

Immunogenicity and safety of 'Comvigen', a bivalent SARS-CoV-2 vaccine, in comparison to Comirnaty bivalent vaccine in Thailand: a phase 2, non-inferiority randomised trial.

Watsamon Jantarabenjakul et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.